[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
1. Brennan P, Coates M, Armstrong B, Colin D, Boffetta P: Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia. Br J Cancer; 2000 Apr;82(7):1344-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used data from the New South Wales Central Cancer Registry to analyse second primary neoplasms following NHL diagnosed between 1972 and 1995, to identify possible common causal agents.
  • A total of 12,452 patients contributed 54,308 person-years of follow-up during which time there were 705 second primary neoplasms compared to 592.99 expected (standardized incidence ratio (SIR = 1.19, 95% confidence interval (CI) 1.10-1.28).
  • There were excesses of melanomas of skin (SIR = 2.38, 95% CI 1.92-2.91), lip cancer (SIR = 2.74, 95% CI 1.59-4.38), tongue cancer (SIR = 2.53, 95% CI 1.09-4.99) and bladder cancer (SIR = 1.64, 95% CI 1.19-2.21).
  • There was also over a threefold excess in soft tissue sarcomas (SIR = 3.61, 95% CI 1.80-6.45) and in thyroid cancer (SIR = 3.42, 95% CI 1.56-6.49).
  • The increases in melanoma of the skin and cancer of the lip and tongue among patients with NHL strongly suggest sunlight exposure as a shared causal agent.
  • The increase in soft tissue sarcomas might be due to shared effects of exposure to chemicals such as phenoxy acid herbicides.
  • The increases in bladder and thyroid cancers are likely to be explained by effects of treatment for NHL.
  • We did not find a chemotherapy related increased risk of myeloid leukaemia among NHL patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Female. Humans. Incidence. Male. Melanoma / epidemiology. Melanoma / etiology. Middle Aged. New South Wales / epidemiology. Registries. Retrospective Studies. Risk Assessment. Skin Neoplasms / epidemiology. Skin Neoplasms / etiology. Sunlight / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Apr 1;67(7):2002-9 [2004317.001]
  • [Cites] Arch Dermatol. 1994 Aug;130(8):1018-21 [8053698.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 5;86(19):1450-7 [8089863.001]
  • [Cites] Int J Epidemiol. 1997 Oct;26(5):945-52 [9363514.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] Br J Cancer. 1996 Apr;73(7):945-50 [8611412.001]
  • [Cites] Am J Epidemiol. 1997 Jun 15;145(12):1061-75 [9199536.001]
  • [Cites] Leuk Lymphoma. 1994 Aug;14(5-6):387-94 [7812197.001]
  • (PMID = 10755412.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] SCOTLAND
  • [Other-IDs] NLM/ PMC2374485
  •  go-up   go-down


2. Kyllönen L, Salmela K, Pukkala E: Cancer incidence in a kidney-transplanted population. Transpl Int; 2000;13 Suppl 1:S394-8
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer incidence in a kidney-transplanted population.
  • A study on cancer incidence after kidney transplantation was performed using data of national transplant and cancer registries.
  • The SIR was highest in skin cancer (39.2).
  • The SIRs were high in cancers of the lip (23.0), thyroid (8.08), kidney (8.0), lower urinary tract (3.2), non-Hodgkin lymphoma (4.8), ovary (3.9) and colon (3.9).
  • Skin cancer and lymphomas had much higher SIRs in men than in women whereas lower urinary tract cancer had a higher SIR in women.
  • During the first 10 follow up years, life-table analysis indicates a higher cancer risk in cyclosporine-treated patients, but this may be biased by their shorter follow up as the overall SIR was equal in both groups.
  • This population study shows the increased incidence of cancer in the transplant population and points out the importance of cancer surveillance in the years following kidney transplantation.
  • [MeSH-minor] Adolescent. Adult. Child. Drug Therapy, Combination. Female. Finland / epidemiology. Follow-Up Studies. Humans. Immunosuppressive Agents / therapeutic use. Incidence. Male. Registries. Retrospective Studies. Sex Factors. Time Factors

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11112040.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


3. Wu CF, Chen CM, Chen CH, Shieh TY, Sheen MC: Continuous intraarterial infusion chemotherapy for early lip cancer. Oral Oncol; 2007 Sep;43(8):825-30
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous intraarterial infusion chemotherapy for early lip cancer.
  • Most lip cancers are usually diagnosed and can be treated with good prognosis at an early stage.
  • This study reports our experience of treating seven, previously untreated, patients with lip cancer in stage I or II using intraarterial infusion chemotherapy with a single agent.
  • In every case the tumor regressed dramatically and disappeared completely after treatment within a mean period of 2.5 months.
  • Only one patient died, of non-disease related pneumonia 3 years after infusion therapy.
  • The side effects of infusion chemotherapy were mild and tolerable.
  • Our technique of continuous intraarterial infusion therapy for treatment of early lip cancers seems to be as effective as other standard techniques such as surgery or radiation therapy.
  • This modality achieves good tumor response rates, an excellent cosmetic result, preservation of function and minimal side effects.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Lip Neoplasms / drug therapy. Methotrexate / administration & dosage
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Follow-Up Studies. Humans. Infusion Pumps, Implantable. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207655.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Yücel A, Cinar C, Aydin Y, Senyuva C, Güzel Z, Cetinkale O, Altintaŝ M: Malignant tumors requiring maxillectomy. J Craniofac Surg; 2000 Sep;11(5):418-29
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumors requiring maxillectomy.
  • Seventy cases with malignant tumors requiring maxillary resection in the past 10 years were reviewed, retrospectively.
  • The primary site of tumor was adjacent skin in 53%, maxillary sinus or maxilla in 20%, palate and alveolar arch in 13%, lip and buccal mucosa in 13%, and mandible in 1% of the cases.
  • Postoperative radiotherapy was performed in 32 patients and combined radiotherapy and chemotherapy in 12 patients.
  • Resection of the tumor with free surgical margins and appropriate evaluation of the surgical defect for the most suitable reconstruction are the mainstays of treatment of the midfacial tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Facial Neoplasms / surgery. Female. Humans. Lip Neoplasms / surgery. Male. Mandible / surgery. Mandibular Neoplasms / surgery. Maxillary Neoplasms / surgery. Maxillary Sinus Neoplasms / surgery. Middle Aged. Mouth Neoplasms / surgery. Neck Dissection. Neoplasm Recurrence, Local / surgery. Orbit Evisceration. Palatal Neoplasms / surgery. Palatal Obturators. Radiotherapy, Adjuvant. Retrospective Studies. Skin Neoplasms / surgery. Skin Transplantation / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11314064.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Güleç AT, Haberal M: Lip and oral mucosal lesions in 100 renal transplant recipients. J Am Acad Dermatol; 2010 Jan;62(1):96-101
MedlinePlus Health Information. consumer health - Mouth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lip and oral mucosal lesions in 100 renal transplant recipients.
  • BACKGROUND: Renal transplant recipients (RTRs) appear to be more susceptible to the development of oral mucosal disease and lip cancer as a result of graft-preserving immunosuppressive therapy.
  • However, reports regarding these pathologies other than lip cancer are scarce and not studied in a detailed manner in this patient population.
  • OBJECTIVE: The aim of this study was to determine the prevalence rates and clinical features of lip lesions and oral mucosal lesions (OMLs) in RTRs.
  • METHODS: In all, 100 consecutive RTRs (21 female and 79 male) and 79 healthy age- and sex-matched control subjects (23 female and 56 male) were screened for all pathologic and pseudopathologic lip lesions and OMLs, with special interest on precancerous and cancerous lesions.
  • RESULTS: One or more lip lesions, OMLs, or both were noted in every participant of both groups.
  • Fordyce spots on the lips was the most common lesion in the patient group (73%), followed by diffuse gingival enlargement (39%), fissured tongue (35%), and oral candidiasis (26%).
  • No actinic cheilitis, lip cancer, or oral malignancy was observed.
  • LIMITATIONS: This was a relatively small sample size for evaluating precancerous and cancerous lip lesions and OMLs, as they are less frequently observed than benign lesions.
  • CONCLUSIONS: Some of the benign OMLs (oral candidiasis and diffuse gingival enlargement) are increased in RTRs mainly as a result of the immunosuppressive therapy or drug side effects.
  • Precancerous or cancerous lesions were not observed on the lips or the oral mucosa of our RTRs.
  • [MeSH-major] Immunocompromised Host. Kidney Transplantation. Lip Diseases / epidemiology. Mouth Diseases / epidemiology
  • [MeSH-minor] Adolescent. Adult. Candidiasis, Oral / epidemiology. Female. Gingiva / pathology. Humans. Hypertrophy. Lip / blood supply. Male. Middle Aged. Mouth Mucosa / pathology. Tongue, Fissured / epidemiology. Varicose Veins / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926164.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Ryuto M, Higaki Y, Tomita K: [Clinical analysis of 16 cases of malignant head and neck melanoma]. Nihon Jibiinkoka Gakkai Kaiho; 2001 Sep;104(9):859-65
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 16 cases of malignant head and neck melanoma].
  • Subjects were 16 patients--5 men and 11 women aged 46-82 years (mean: 61 years)--with malignant melanoma of the head and neck treated at our clinic from 1972 to 1988.
  • Histologically, 1 subjects was amelanotic and 15 melanotic type.
  • Primary lesions were 10 involving the nasal cavity, 2 the paranasal sinus, 2 the gingiva, 1 the lip, and 1 primary unknown.
  • They were treated with or without multimodal surgery, radiation, chemotherapy, and immunotherapy.
  • The prognosis of malignant head and neck melanoma is poor but has gradually improved due to preoperative decisions on disease spread and the introduction of multimodal therapy.
  • [MeSH-major] Head and Neck Neoplasms / therapy. Melanoma / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11605226.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Kovács AF, Ghahremani MT, Stefenelli U, Bitter K: Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results. J Chemother; 2003 Oct;15(5):495-502
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results.
  • Adjuvant chemotherapy has not yet been proven to have a survival benefit for patients with head and neck cancer.
  • Studies dealing with this topic have had several faults like mingling tumor localizations and treatment modalities.
  • To re-examine the role of postoperative chemotherapy in oral cavity cancer, a single-center study was conducted with the attempt to have higher homogeneity.
  • 122 patients with primary squamous cell carcinoma of the lip, the oral cavity and the oropharynx have been treated with 100 mg/m2 cisplatin bolus infusion and 120-h continuous infusion of 1000 mg/m2 5-fluorouracil following radical surgery; 99 patients completed all 3 cycles.
  • The disease-free and overall survival are reported and compared to a control group of 161 patients with cancer of the lip, the oral cavity and oropharynx treated only with surgery, and a treatment-dependent prognostic index.
  • After a median follow-up of 79 months (range 5-18 years), the current 5-year overall survival of the chemotherapy group was 67% and the 5-year disease-free survival was 57% while the respective data for the control group are 46% and 40%.
  • The chemotherapy group suffered from fewer local and more neck relapses and had a much longer relapse latency (29 months versus 8 months).
  • The toxicity of the chemotherapy regimen was tolerable.
  • In a homogeneous population with resectable oral cavity and oropharyngeal cancer, postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil resulted in a high overall survival rate which was significantly better than in a comparable population treated only with surgery and better than the survival expectation calculated with the help of a prognostic index.
  • A prospective randomized study of postoperative chemotherapy versus control, exclusively in patients with oral cancer, is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Lip Neoplasms / drug therapy. Lip Neoplasms / surgery. Mouth Neoplasms / drug therapy. Mouth Neoplasms / surgery. Neoplasm Recurrence, Local. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14598943.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Penn I: Post-transplant malignancy: the role of immunosuppression. Drug Saf; 2000 Aug;23(2):101-13
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunosuppressed organ allograft recipients have a 3- to 4-fold increased risk of developing tumours, but the risk of developing certain cancers is increased several hundredfold.
  • With the exception of skin and lip cancers, most of the common malignancies seen in the general population are not increased in incidence.
  • Skin and lip cancers present some unusual features: a remarkable frequency of KS, reversal of the ratio of basal to squamous cell carcinomas seen in the general population, the young age of the patients, and the high incidence of multiple tumours (in 43% of the patients).
  • Anogenital cancers occur at a much younger age than in the general population.
  • As the immunosuppressed state per se and various potentially oncogenic viruses play a major role in causing these cancers, preventative measures include reducing immunosuppression to the lowest level compatible with good allograft function and prophylactic measures against certain virus infections.
  • Reduction of exposure to sunlight may also decrease the incidence of skin cancer.
  • In addition to conventional treatments (resection, radiation therapy, chemotherapy) patients may receive antiviral drugs, interferon-alpha and various other manipulations of the immune system.
  • A significant percentage of cases of PTLD and KS respond to reduction or cessation of immunosuppressive therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Nephrol. 1994;14(2):121-6 [8080004.001]
  • [Cites] Lancet. 1982 Aug 14;2(8294):381-2 [6124778.001]
  • [Cites] Oncogene. 1997 Oct 2;15(14):1737-40 [9349508.001]
  • [Cites] Transplantation. 1995 Dec 27;60(12):1485-91 [8545879.001]
  • [Cites] Clin Transplant. 1996 Oct;10(5):429-31 [8930456.001]
  • [Cites] Immunol Rev. 1992 Jun;127:147-55 [1506004.001]
  • [Cites] Transplant Proc. 1996 Apr;28(2):876-8 [8623443.001]
  • [Cites] Transplant Proc. 1993 Feb;25(1 Pt 2):1383-4 [8442150.001]
  • [Cites] Thorax. 1988 Aug;43(8):653-6 [3051511.001]
  • [Cites] Crit Rev Oncog. 1989;1(1):27-52 [2488123.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1333-5 [7557890.001]
  • [Cites] Transplant Proc. 1969 Mar;1(1):106-12 [4944206.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):183-9 [7829213.001]
  • [Cites] Liver Transpl Surg. 1996 Sep;2(5):375-82 [9346679.001]
  • [Cites] Am J Obstet Gynecol. 1984 Oct 1;150(3):300-8 [6091459.001]
  • [Cites] Nephrol Dial Transplant. 1994;9(4):443-5 [8084464.001]
  • [Cites] Transplantation. 1988 Apr;45(4):719-27 [2833828.001]
  • [Cites] J Clin Microbiol. 1997 Jun;35(6):1612-5 [9163497.001]
  • [Cites] Clin Transplant. 1992;6(Spec):249-252 [21151749.001]
  • [Cites] Cancer. 1976 Feb;37(2):729-34 [766948.001]
  • [Cites] Transplant Sci. 1994 Sep;4(1):23-32 [7804694.001]
  • [Cites] Transplant Proc. 1999 Feb-Mar;31(1-2):1260-2 [10083562.001]
  • [Cites] Hum Exp Toxicol. 1995 Jan;14(1):98 [7748628.001]
  • [Cites] Transplantation. 1995 Jan 27;59(2):240-4 [7839447.001]
  • [Cites] Hematol Oncol Clin North Am. 1993 Apr;7(2):467-75 [8385662.001]
  • [Cites] Br J Plast Surg. 1994 Mar;47(2):86-9 [8149064.001]
  • [Cites] Lancet. 1984 Mar 17;1(8377):583-7 [6142304.001]
  • [Cites] Transplantation. 1998 Oct 15;66(7):851-6 [9798693.001]
  • [Cites] Ann Intern Med. 1997 Jun 1;126(11):882-5 [9163289.001]
  • [Cites] Transplant Sci. 1994 Sep;4(1):46-60 [7804697.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] Immunol Rev. 1997 Jun;157:217-22 [9255632.001]
  • [Cites] J Invest Dermatol. 1997 May;108(5):708-11 [9129219.001]
  • [Cites] Lancet. 1989 Jul 22;2(8656):224-5 [2568556.001]
  • [Cites] Transplantation. 1990 Mar;49(3):506-9 [2316011.001]
  • [Cites] Am J Med. 1988 Feb;84(2):225-32 [3044069.001]
  • [Cites] Transplantation. 1998 Aug 27;66(4):493-9 [9734494.001]
  • [Cites] Am J Med. 1979 Nov;67(5):759-65 [159624.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1933-8 [7636533.001]
  • [Cites] Transplantation. 1995 Jan 15;59(1):135-8 [7839414.001]
  • [Cites] Liver Transpl Surg. 1998 Mar;4(2):146-51 [9516567.001]
  • [Cites] Transplantation. 1995 Feb 27;59(4):480-5 [7878750.001]
  • [Cites] Transplantation. 1997 Sep 15;64(5):669-73 [9311700.001]
  • [Cites] Transplantation. 1997 Jun 15;63(11):1691-4 [9197369.001]
  • [Cites] Ann Transplant. 1997;2(4):33-40 [9869877.001]
  • [Cites] Annu Rev Med. 1995;46:381-94 [7598473.001]
  • [Cites] Transplantation. 1998 Dec 27;66(12):1604-11 [9884246.001]
  • [Cites] Nature. 1986 Aug 7-13;322(6079):502-3 [3461283.001]
  • [Cites] Am J Surg. 1998 Sep;176(3):265-9 [9776156.001]
  • [Cites] Transplantation. 1997 May 15;63(9):1200-5 [9158009.001]
  • [Cites] Obstet Gynecol. 1975 Apr;45(4):359-64 [1091896.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1141-50 [9305716.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] Am J Med. 1985 Jan 21;78(1A):44-9 [3970040.001]
  • [Cites] Photochem Photobiol. 1986 Mar;43(3):257-62 [3703959.001]
  • [Cites] Transplantation. 1989 Mar;47(3):458-64 [2538015.001]
  • [Cites] Transplantation. 1985 Jan;39(1):23-5 [3880960.001]
  • [Cites] Br J Dermatol. 1985 Dec;113(6):723-9 [3913458.001]
  • [Cites] Springer Semin Immunopathol. 1998;20(3-4):343-55 [9870250.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] Transplant Sci. 1994 Sep;4(1):42-5 [7804696.001]
  • [Cites] Ann Transplant. 1997;2(4):28-32 [9869876.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1712-7 [8970360.001]
  • (PMID = 10945373.001).
  • [ISSN] 0114-5916
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 71
  •  go-up   go-down


9. Ryu S, Khan M, Yin FF, Concus A, Ajlouni M, Benninger MS, Kim JH: Image-guided radiosurgery of head and neck cancers. Otolaryngol Head Neck Surg; 2004 Jun;130(6):690-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-guided radiosurgery of head and neck cancers.
  • OBJECTIVES: Radiosurgery precisely delivers a single high dose or a few fractionated doses of radiation to a localized tumor via the stereotactic approach.
  • The clinical studies were carried out to determine the accuracy of stereotactic radiosurgery and to demonstrate the effectiveness of radiosurgery in head and neck cancers.
  • MATERIALS AND METHODS: Thirteen patients were treated with either single-dose or fractionated radiosurgery to the tumor.
  • All patients except one with cancer of the lip had received prior treatments including surgery, radiotherapy, and chemotherapy for the primary cancers.
  • The dose ranged 12 to 18 Gy for single-dose radiosurgery and 30 Gy in 5 or 6 fractions twice a week for fractionated radiosurgery.
  • Tumor localization was achieved via the stereotactic approach.
  • Despite the recurrent disease from previous heavy treatments, 9 patients (70%) showed a significant response (complete or >50% tumor reduction) to radiosurgery, and 3 patients had stable disease.
  • Complete tumor response was achieved in 6 patients.
  • CONCLUSION: Image-guided radiosurgery is effective in achieving the local tumor control and pain relief.
  • The results indicate the potential of radiosurgery in the treatment of recurrent and selected primary head and neck cancers.
  • [MeSH-minor] Combined Modality Therapy. Dose Fractionation. Follow-Up Studies. Humans. Stereotaxic Techniques

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15195054.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S, Swiss HIV Cohort: Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst; 2005 Mar 16;97(6):425-32
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
  • BACKGROUND: Persons infected with human immunodeficiency virus (HIV) have an increased risk for several cancers, but the influences of behavioral risk factors, such as smoking and intravenous drug use, and highly active antiretroviral therapy (HAART) on cancer risk are not clear.
  • METHODS: Patient records were linked between the Swiss HIV Cohort Study and Swiss cantonal cancer registries.
  • Observed and expected numbers of incident cancers were assessed in 7304 persons infected with HIV followed for 28,836 person-years.
  • Relative risks for cancer compared with those for the general population were determined by estimating cancer registry-, sex-, age-, and period-standardized incidence ratios (SIRs).
  • Statistically significantly elevated SIRs were also observed for anal cancer (SIR = 33.4, 95% CI = 10.5 to 78.6); Hodgkin lymphoma (SIR = 17.3, 95% CI = 10.2 to 27.4); cancers of the cervix (SIR = 8.0, 95% CI = 2.9 to 17.4); liver (SIR = 7.0, 95% CI = 2.2 to 16.5); lip, mouth, and pharynx (SIR = 4.1, 95% CI = 2.1 to 7.4); trachea, lung, and bronchus (SIR = 3.2, 95% CI = 1.7 to 5.4); and skin, nonmelanomatous (SIR = 3.2, 95% CI = 2.2 to 4.5).
  • No clear impact of HAART on SIRs emerged for cervical cancer or non-acquired immunodeficiency syndrome-defining cancers.
  • Cancers of the lung, lip, mouth, or pharynx were not observed among nonsmokers.
  • CONCLUSION: In persons infected with HIV, HAART use may prevent most excess risk of KS and non-Hodgkin lymphoma, but not that of Hodgkin lymphoma and other non-acquired immunodeficiency syndrome-defining cancers.
  • No cancers of the lip, mouth, pharynx, or lung were observed in nonsmokers.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. CD4-Positive T-Lymphocytes. HIV Infections / complications. HIV Infections / drug therapy. Neoplasms / epidemiology. Neoplasms / etiology. Smoking / adverse effects

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Mar 16;97(6):407-9 [15769998.001]
  • (PMID = 15770006.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Kübler AC, de Carpentier J, Hopper C, Leonard AG, Putnam G: Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy. Int J Oral Maxillofac Surg; 2001 Dec;30(6):504-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy.
  • Carcinoma of the lip is a common cancer of the head and neck area; its incidence is approximately one-quarter that for oral cavity cancers.
  • It occurs most frequently on the lower lip of elderly males.
  • This non-randomized Phase II study aimed to estimate the complete response (CR) rate to Foscan-mediated photodynamic therapy (Foscan-PDT) in patients with primary cancer of the lip, duration of CR, and the tolerability and safety of Foscan-PDT.
  • Twenty-five patients with squamous cell carcinoma (SCC) of the lip (Tis, T1, T2/N0/M0) and Karnofsky status > or = 70 received 0.15 mg/kg Foscan intravenously, followed 4 days later by a single non-thermal illumination of the tumour (light dose 20 J/cm2, irradiance 100 mW/cm2, lambda=652 nm).
  • The most common adverse event was swelling and local pain at the treatment site.
  • Tumour recurrence was observed in two patients 4 and 18 months after PDT.
  • One patient developed a single lymph node metastasis 7 months after therapy.
  • The functional results were excellent in all patients without any signs of limited mouth opening or impaired lip closure.
  • The cosmetic outcome was better than after surgical therapy.
  • Foscan-PDT is an effective treatment modality for small primary tumours of the lips.
  • It allows preservation of form and function and does not compromise future treatment options for recurrent, residual or second primary disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Lip Neoplasms / drug therapy. Mesoporphyrins / therapeutic use. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Female. Follow-Up Studies. Humans. Injections, Intravenous. Laser Therapy. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Photosensitivity Disorders / chemically induced. Prospective Studies. Radiation Dosage. Remission Induction. Safety. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11829232.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


12. Yücesoy G, Kus E, Cakiroglu Y, Muezzinoglu B, Yildiz K, Yucesoy I: Primary malignant melanoma of the cervix: report of a case. Arch Gynecol Obstet; 2009 Apr;279(4):573-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the cervix: report of a case.
  • BACKGROUND: To present a case of primary malignant melanoma of the cervix.
  • Gynecological examination revealed a dark, papillary mass on the posterior lip of the cervix.
  • Histopathology showed a malignant neoplasm with increased vascularity, indicating the possibility of a primary uterine cervical melanoma.
  • Diagnosis of malignant melanoma was confirmed with immunohistochemistry, which showed diffuse positive reactions for S-100 protein and HBM-45, with no reaction for epithelial markers, namely cytokeratin AE1/AE3 and epithelial membrane antigen.
  • The tumor was stage IB1 according to the International Federation of Gynecology and Obstetrics classification.The patient underwent radical Wertheim-Meigs hysterectomy, bilateral salpingo-oopherectomy, and retroperitoneal pelvic lympadenectomy.
  • Radiotherapy or chemotherapy was not performed in the postoperative period.
  • CONCLUSION: Primary malignant melanoma of the cervix is a rare cervical malignancy.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726108.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Hicks J, Flaitz C: Mucoepidermoid carcinoma of salivary glands in children and adolescents: assessment of proliferation markers. Oral Oncol; 2000 Sep;36(5):454-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant neoplasms represent one-third of all pediatric salivary gland tumors.
  • Mucoepidermoid carcinoma (MEC) composes 51% of malignant tumors and 16% of all salivary gland neoplasms in pediatrics.
  • Proliferation was assessed by determining the percentage of tumor cells immunoreactive for PCNA and Ki-67.
  • Tumor site was 16 parotid, eight submandibular, one base of tongue and one maxillary lip.
  • Median tumor size was 2.5 cm (range 1.5-5 cm).
  • Mean percentage of tumor cells immunoreactive for proliferation markers is as follows: PCNA: LG 9%, IG 17%, HG 32%; and Ki-67: LG 7%, IG 12%, HG 26%.
  • Treatment was surgical in 21 cases, and surgery with chemotherapy and radiotherapy in five cases.
  • MECs were second malignancies in two children with prior radiotherapy and chemotherapy for leukemia and histiocytosis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Mucoepidermoid / chemistry. Salivary Gland Neoplasms / chemistry
  • [MeSH-minor] Adolescent. Cell Division. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Ki-67 Antigen / chemistry. Male. Neoplasm Staging. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10964053.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


14. Rock JP, Hearshen D, Scarpace L, Croteau D, Gutierrez J, Fisher JL, Rosenblum ML, Mikkelsen T: Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery; 2002 Oct;51(4):912-9; discussion 919-20
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The differentiation of tumor recurrence from radiation necrosis in patients with malignant gliomas who have been treated previously remains a challenge.
  • Magnetic resonance imaging, single-photon emission computed tomography, and positron emission tomography cannot provide definitive histopathological insight.
  • METHODS: Twenty-seven patients who had been treated previously with surgery, radiotherapy, and chemotherapy and reoperated for clinical and/or radiographic signs that caused suspicion for recurrent disease were studied.
  • Tissues were categorized into four groups: spectroscopically normal, pure tumor, mixed tumor and radiation necrosis, and pure radiation necrosis.
  • Spectral data for choline (Cho), lipid-lactate (Lip-Lac), N-acetylaspartate, and creatine (Cr) were analyzed as Cho/normal Cr (nCr), Lip-Lac/Cho, Lip-Lac/nCr, N-acetylaspartate/Cho, N-acetylaspartate/nCr, and Cho/normal Cho (nCho).
  • Logistic regression analysis was performed on the basis of data obtained from 99 (1)H MRSI observations to determine whether the (1)H MRSI ratios varied according to tissue category.
  • RESULTS: (1)H MRSI ratios were found to distinguish pure tumor from pure necrosis.
  • The odds of a biopsy's being pure tumor and having either a Cho/nCr value greater than 1.79 or a Lip-Lac/Cho value less than 0.75 are seven times the odds of that biopsy's being pure necrosis (odds ratio, 7.00; P = 0.0136).
  • The odds of a biopsy's being pure necrosis and having either a Cho/nCr value less than 0.89 or a Cho/nCho value less than 0.66 are six times the odds of that biopsy's being pure tumor (odds ratio, 5.71; P = 0.0329).
  • The odds of a biopsy's being pure necrosis and having either a Lip-Lac/Cho value greater than 1.36 or a Lip-Lac/nCr value greater than 2.84 are more than five times the odds of the biopsy's being pure tumor (odds ratio, 5.25; P = 0.0322).
  • In addition, although only marginally significant, Lip-Lac/Cho and Lip-Lac/nCr ratios distinguish pure tumor from pure necrosis.
  • No values suggested that mixed specimens could be distinguished in a statistically significant way from either pure tumor or pure necrosis.
  • CONCLUSION: The data that we gathered suggest that metabolite ratios derived on the basis of (1)H MRSI spectral patterns do allow reliable differential diagnostic statements to be made when the tissues are composed of either pure tumor or pure necrosis, but the spectral patterns are less definitive when tissues composed of varying degrees of mixed tumor and necrosis are examined.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Glioma / pathology. Glioma / radiotherapy. Magnetic Resonance Spectroscopy. Radiation Injuries / diagnosis
  • [MeSH-minor] Adult. Choline / metabolism. Creatine / metabolism. Diagnosis, Differential. Humans. Lactic Acid / metabolism. Lipid Metabolism. Necrosis. Neoplasm Recurrence, Local / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12234397.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 33X04XA5AT / Lactic Acid; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


15. Guntinas-Lichius O, Wendt T, Buentzel J, Esser D, Lochner P, Mueller A, Schultze-Mosgau S, Altendorf-Hofmann A: Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database. J Cancer Res Clin Oncol; 2010 Jan;136(1):55-63
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database.
  • OBJECTIVE: To describe epidemiology and prognosis of head and neck cancer in Germany.
  • METHODS: We analyzed the Thuringian cancer registry database from 1996 to 2005.
  • 3,821 cases with primary head and neck cancer were evaluated for patient's characteristics, tumor stage, incidence, treatment, and trends in overall survival.
  • RESULTS: During the period 1996-2005, the incidence of oropharynx, hypopharynx, larynx, and salivary gland cancer increased significantly for males, and of oral cavity and hypopharynx cancer for females.
  • There was a significant trend using more multimodal therapy combining surgery, radiotherapy, and chemotherapy, and to use less radiotherapy as a single modality.
  • The median follow-up time of patients alive was 42 months.
  • The site-specific 5-year OS for lip, oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, salivary gland, and nose/paranasal sinus cancer was 75.7, 42.6, 43.5, 45.9, 27.2, 57.3, 61.0, and 34.9%, respectively.
  • The multivariate analysis showed that male gender, age ≥ 60 years, therapy without surgery, higher T classification, N classification, and M classification were independent significant negative risk factors for OS (p < 0.0001).
  • Cancer of the oral cavity and of the hypopharynx had a significant lower OS than lip cancer (p = 0.012 and p = 0.044, respectively).
  • CONCLUSIONS: Many subsites of head and neck cancer have changing incidence.
  • Although treatment strategies have changed, outcome has not improved significantly from 1995 to 2006.
  • [MeSH-major] Databases, Factual / statistics & numerical data. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / therapy. Registries / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Germany / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Public Health. 2006 Jun 06;6:146 [16756650.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1143-54 [18784104.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2201-7 [9827726.001]
  • [Cites] Head Neck. 2005 Oct;27(10):843-50 [16161069.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Sep;135(3):451-7 [16949981.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):784-96 [17714993.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2901-9 [18980273.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Sep;124(9):951-62 [9738803.001]
  • [Cites] Z Gerontol Geriatr. 2005 Feb;38(1):47-59 [15756487.001]
  • [Cites] Mayo Clin Proc. 2008 Apr;83(4):489-501 [18380996.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):221-8 [18544437.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Eur Addict Res. 2003 Oct;9(4):147-56 [12970583.001]
  • [Cites] Laryngorhinootologie. 2002 Jul;81(7):499-508 [12173061.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):806-16 [15609302.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • (PMID = 19568769.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Stanko P, Satko I, Czako L, Beno M, Danko J, Zmeko S: Squamous cell carcinoma of the oral cavity. Bratisl Lek Listy; 2007;108(7):292-6
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: A number of treatment modalities are available in the management of oral cavity cancer.
  • These are surgery (operation OP), irradiation (radiotherapy RT), chemotherapy (CHT), or complex therapy performed as a combination of the later three methods with various survival rates.
  • BACKGROUND AND METHODS: Authors analysed retrospectively a group of 622 patients (553 men, 69 women), mean age 58.6 years (range 23-88 years) hospitalised in the Department of Oral and Maxillofacial Surgery, Faculty Hospital and Faculty of Medicine Comenius University in Bratislava within the years 1992-2001 with primary untreated histologically confirmed squamous cell carcinoma of oral cavity (beside cancer of the lip and salivary glands).
  • Gender, age, location and TNM staging of the disease, clinical and histopathological evaluations of the neck lymph nodes and relationship to the treatment modalities were recorded.
  • Regarding the complexity of treatment, the best 5-year survival rates showed the complex three-modal therapy (CHT + OP + RT = 23.5%), comparing to the dual (OP + RT or CHT + RT = 19.4%) and mono-modal therapy (OP or RT alone = 17.2%).
  • In the complex therapy, the mean disease-free interval improved (30.2 vs 39.4 months) due to a change in the sequence of therapy modalities.
  • In spite of the fact that the overal 5-year survival was found not to improve, the quality of life regarding the mean disease-free interval in the group of patients under the complex treatment is considered to be a positive result (Tab. 3, Fig.


17. Liang XH, Wang SZ, Mao ZY: [Effects of thermochemotherapy on immunologic function of patients with lip cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Mar;35(2):220-2
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of thermochemotherapy on immunologic function of patients with lip cancer].
  • OBJECTIVE: To evaluate the effects of thermochemotherapy on the immunologic function of lip cancer patients and to provide a theoretical basis for the clinical application of thermochemotherapy.
  • Each of the patients received the therapy twice a week for 5 weeks.
  • The lymphocyte transformation index after treatment was significantly higher than that before treatment (P < 0.01).
  • The CD4+ T cells and CD4+/CD8+ after treatment were significantly higher than those before treatment (P < 0.05); the CD8+ T cells after treatment was lower than that before treatment, but there was no statistically significant difference (P > 0.05).
  • CONCLUSION: Thermochemotherapy can enhance the lip cancer patient's T lymphocyte immunologic function, which possibly plays an important role in the treatment of lip cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / analogs & derivatives. Lip Neoplasms / drug therapy. Lip Neoplasms / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Aged. Aged, 80 and over. CD4-CD8 Ratio. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / immunology. Female. Hot Temperature. Humans. Lymphocyte Activation. Male. Methotrexate / administration & dosage. Microwaves. Middle Aged

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15071922.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 77108-50-0 / zhengguangmycin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Zhang WC, Cheng JP, Li Q, Zhang L, Wang XD, Anniko M: Clinical and pathological analysis of malignant carotid body tumour: a report of nine cases. Acta Otolaryngol; 2009 Nov;129(11):1320-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological analysis of malignant carotid body tumour: a report of nine cases.
  • CONCLUSIONS: Malignant carotid body tumour (MCBT) is a clinically rare disease that often invades the carotid artery and cranial nerves.
  • Diagnosis of malignant tumour should be based on extensive invasion of neighbouring organs and distant metastasis.
  • Radiotherapy is effective, whereas chemotherapy is uncertain.
  • OBJECTIVE: To summarize the clinical pathological and prognostic characteristics of MCBT and explore methods for diagnosis and treatment.
  • MATERIALS AND METHODS: The study material comprised clinical, pathological, therapeutic and follow-up data concerning nine patients (four males, five females) with MCBT, treated at Tianjin Cancer Hospital between January 1956 and June 2006.
  • Shamblin classification was: one case, type II; 8 cases, type III.
  • Eight patients suffered from a cranial nerve dysfunction (defect) and two suffered postoperatively from a hoarse voice, four had a glossal deviation, five had Horner's syndrome and one had a deviation of the lip angle.
  • The histopathological diagnosis in all nine cases was MCBT.
  • [MeSH-major] Carotid Body Tumor / surgery
  • [MeSH-minor] Adult. Carotid Arteries / pathology. Carotid Arteries / surgery. Combined Modality Therapy. Cranial Nerves / pathology. Disease Progression. Disease-Free Survival. Female. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology. Magnetic Resonance Angiography. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Positron-Emission Tomography. Postoperative Complications / etiology. Radiotherapy, Adjuvant. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863331.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement